DUBLIN--(BUSINESS WIRE)--The "Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors - Competitive Landscape, Market and Pipeline Analysis 2017" drug pipelines has been added to Research and Markets' offering.
Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors - Competitive Landscape, Market and Pipeline Analysis 2017 provides comprehensive insights about pipeline drugs across Cyclin Dependent Kinase 4/6 inhibitors. A key objective of the report is to establish the understanding for the therapeutic competitive landscape for this mechanism of action. It provides the marketed product details in this area.
It also covers the pipeline drugs that fall under Cyclin Dependent Kinase 4/6 inhibitors including their comparative analysis at various stages covering Filed, Phase II, Phase I, Pre-clinical, and inactive products, therapeutics assessment by monotherapy and combination products and molecule type. The report also provides the market drivers and barriers for CDK 4/6 inhibitors.
Key Topics Covered:
- Executive Summary
- Overview
- Marketed Drugs
- Pipeline Therapeutics
- Last Stage Products (Phase III)
- Mid Stage Products (Phase II)
- Early Stage Products (Phase I)
- Pre-clinical Stage Products
- Therapeutic Assessment: Active Products
- Inactive Products
- Market Drivers and Barriers
- Appendix
Companies Mentioned
- Astex
- BetaPharma
- Eli Lilly
- FLXBIO
- G1 Therapeutics
- Jiangsu HengRui Medicine
- MetaMax
- Novartis
- Onconova
- Pfizer
- Presage Biosciences
- Sumitomo Dainippon Pharma
- Tragara
- Triziana Life Sciences
- ViroStatics
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/d9bf55/cyclin_dependent
